Trial
NCT01905592
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Tesaro, Inc.
Collaborators
European Organisation for Research and Treatment of Cancer - EORTC; Breast International Group; Myriad Genetic Laboratories, Inc.; US Oncology Research; Sarah Cannon; Facing Our Risk of Cancer Empowered
Condition
Neoplasms, Breast
Intervention
niraparib
Why stopped
The study was terminated due to futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-15